Oct 8 (Reuters) - Johnson & Johnson JNJ.N :
* JOHNSON & JOHNSON ANNOUNCES EUROPEAN COMMISSION APPROVAL OF AGREEMENT TO SUPPLY 200 MILLION DOSES OF JANSSEN'S COVID-19 VACCINE CANDIDATE
* J&J - AGREEMENT PROVIDES OPTION FOR EUROPEAN UNION MEMBER STATES TO SECURE UP TO 200 MILLION ADDITIONAL DOSES FOR A TOTAL OF UP TO 400 MILLION DOSES
* J&J - PLANS TO ALLOCATE UP TO 500 MILLION VACCINE DOSES TOWARD INTERNATIONAL EFFORTS TO ENSURE ACCESS FOR LOWER INCOME COUNTRIES
* J&J - ONGOING DISCUSSIONS WITH OTHER STAKEHOLDERS AS PART OF ITS EFFORTS TO MEET ITS COMMITMENT TO MAKE ITS COVID VACCINE CANDIDATE ACCESSIBLE GLOBALLY
* J&J - WORKING TO FURTHER EXPAND NUMBER OF AVAILABLE DOSES OF JANSSEN'S COVID-19 VACCINE CANDIDATE
* J&J - SECOND PHASE 3 STUDY WITH A TWO-DOSE REGIMEN IS PLANNED TO START LATER THIS YEAR
* J&J - TO DATE, MORE THAN 100,000 INDIVIDUALS HAVE BEEN VACCINATED WITH A JANSSEN ADVAC-BASED VACCINE.
* J&J - ANTICIPATE COVID-19 VACCINE CANDIDATE TO BE COMPATIBLE WITH STANDARD DISTRIBUTION CHANNELS WITHOUT NEED FOR NEW DISTRIBUTION INFRASTRUCTURE